Eli Lilly announces trial results of new weight loss, diabetes pill; stock booms
Show Caption
Hide Caption
Eli Lilly lowering price of Zepbound
Hugely popular weight loss drugs known as GLP-1's are finally getting cheaper, well at least one is, and that's the case with Eli Lilly drug Zettbound.
Cheddar
Eli Lilly's stock boomed April 17 after announcing a new experimental pill that caused nearly 8% weight loss at certain dosages and lowered blood sugar in patients during a clinical trial.
The Indianapolis-headquartered pharmaceutical company, known for selling weight loss drugs Mounjaro and Zepbound, published its findings for the pill called orforglipron in a news release on April 17.
"We are pleased to see that our latest incretin medicine meets our expectations for safety and tolerability, glucose control and weight loss, and we look forward to additional data readouts later this year," said David A. Ricks, Lilly's chair and CEO.
According to Ricks, orforglipron is a once-daily pill that, if approved, could be "readily manufactured and launched at scale for use by people around the world."
Eli Lilly stock booms April 17
Lilly's shares had increased roughly 16% by 1 p.m. ET after the results of the trial were released.
What does Lilly's new pill do?
Lilly said its new pill would continue the company's "mission to reduce chronic diseases like type 2 diabetes," which it says is expected to roughly impact 760 million adults by 2050.
During the trial, the pill lowered patients' A1C by an average of 1.3% to 1.6% from a baseline of 8.0%, according to Lilly. The company also said that more than 65% of patients taking the highest dose of orforglipron reached an A1C less than or equal to 6.5%, which is below the American Diabetes Association's (ADA) defined threshold for diabetes.
For people without diabetes, a normal A1C is below 5.7%, the Cleveland Clinic says. Between 5.7% and 6.4% is considered prediabetes, it added.
Patients taking the highest dose of Lilly's new pill lost an average of 16 pounds during the trial, according to the company. Participants' weight loss had not yet plateaued by the time the trial ended, which could indicate further weight reduction was possible, Lilly said.
When will Lilly's new pill be available to public?
It is unclear when Lilly's new pill will be made available to the public, as more trials will be conducted and it faces approval by the Food and Drug Administration (FDA).
Ricks said this is only the first of seven Phase 3 studies "examining the safety and efficacy of orforglipron across people with diabetes and obesity."
What are the adverse effects of Lilly's new pill?
So far, Lilly said the adverse effects of its new pill are consistent with GLP-1s, a class of medications primarily used to treat type 2 diabetes.
The most commonly reported side effects were "gastrointestinal-related and generally mild to moderate in severity," Lilly said. The trial found that different doses (3 mg, 12 mg and 36 mg) caused varying chances of side effects, which included diarrhea (19%, 21% and 26%), nausea (13%, 18% and 16%), dyspepsia (10%, 20% and 15%), constipation (8%, 17% and 14%) and vomiting (5%, 7% and 14%).
"With some concern of elevated rates of nausea and vomiting heading into today's readout, these result firmly validate the tolerable profile of orforglipron," BMO Capital Markets analyst Evan Seigerman said, per Reuters.
Additionally, no liver-related safety signal was observed in the trial, Lilly said.
How would people take Lilly's new pill?
Lilly's new pill can be taken at any time of the day without restrictions on food and water intake, according to the company.
Contributing: Reuters
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
14 minutes ago
- Newsweek
Gen Z and Millennials Have Differing Views on Ozempic
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Gen Z and millennials have radically different views on GLP-1s like Ozempic and how much they want the weight loss and diabetes drugs regulated, according to a new report from GLP-1 prescription weight loss company Levity. While 40 percent of current and recent GLP-1 (glucagon-like peptide-1) users said the current regulations are fair, 28 percent want fewer rules and 22 percent said there should be more. But in the millennial age group, users tend to want less regulation, while Gen Z leaned toward more. Why It Matters GLP-1s, which are injectable drugs that mimic hormones to reduce blood sugar and promote weight loss, have skyrocketed in popularity in recent years. Popular products, including Ozempic, Mounjaro, Wegovy and Zephound, have been a game changer for many Americans who are obese or have type 2 diabetes. However, stricter FDA rules are now in effect, banning certain compounded GLP-1s and making it more difficult for many Americans to secure the drugs, especially if using it for weight loss reasons. Ozempic is medicine for adults with type 2 diabetes. Ozempic is medicine for adults with type 2 diabetes. Steve Christo - Corbis/Corbis via Getty Images What To Know The Gen Z and millennial response to the stricter FDA rules have been notably different, according to Levity. At 31 percent, millennials were the most likely to favor fewer GLP-1 regulations compared to 19 percent of the group who wanted more. Gen Z, meanwhile, favored stricter rules at 37 percent, while 32 percent wanted fewer. "Millennials are more likely to be prescribed a GLP-1 as compared to Gen Z; therefore, it is not surprising that millennials desire less regulation on these drugs," Richard Frank, MD, MHSA, and chief medical officer at Vida Health, told Newsweek. "Having said that, the regulatory environment surrounding compounded agents, in general, and compounded GLP-1s, specifically, is not as rigorous as it is for branded and generic drugs. Therefore, compounded drugs carry unknown risks that more regulated medications do not." Because semaglutide is no longer on the FDA shortage list, compounding it can carry legal risks. Already, the effects are being felt, as 17 percent of GLP-1 users said it has become harder to get their medication since the FDA tightened rules on compounded semaglutide, Levity reported. There was also a difference in how the generations viewed their use of the drugs. While 75 percent of GLP-1 users believed they'll still be on their treatment plan a year from now, Gen Z was the least likely to think so, at 58 percent. What People Are Saying Board-certified endocrinologist Dr. Caroline Messer told Newsweek: "Millennials, many of whom are now managing midlife weight and metabolic health concerns, may see GLP-1s as a practical tool and want fewer barriers. Gen Z, meanwhile, is generally more wary of long-term unknowns, hence leaning toward more safeguards. Broadly, Americans are divided but lean toward keeping current regulations." Richard Frank, MD, MHSA, and chief medical officer at Vida Health, told Newsweek: "From a business perspective, limiting access to compounded drugs when branded drugs are available protects the drug companies' patents. This protection provides the financial incentive for drug companies to develop innovative new therapies." What Happens Next The long-term effects of GLP-1 medication use are so far unclear. A recent study discovered a new link between taking GLP-1 drugs and elevated risk of pancreatitis and kidney conditions, including kidney stones. And GLP-1 medications have also been associated with a higher risk of digestive problems, including nausea, vomiting, diarrhea and even stomach paralysis in rare cases.
UPI
44 minutes ago
- UPI
Dallas Cowboys owner Jerry Jones discloses decade-long cancer battle
1 of 5 | Dallas Cowboys owner Jerry Jones said he was diagnosed with cancer in 2010. File Photo by Ian Halperin/UPI | License Photo Aug. 13 (UPI) -- Jerry Jones was diagnosed with stage 4 melanoma and underwent four surgeries over more than a decade to beat the cancer, the Dallas Cowboys owner revealed. Jones made the disclosure during an interview published Wednesday in the Dallas Morning News. The 82-year-old billionaire, who said he was diagnosed in 2010, credited an experimental drug with saving his life. He received treatment at MD Anderson Cancer Center in Houston. "I was saved by a fabulous treatment and great doctors and a real miracle called PD-1 [therapy]," Jones told the Morning News. "I went into trials for that PD-1 and it has been one of the great medicines. I now have no tumors." Stage 4 melanoma means the cancer has already spread to other areas of the body, including the distant lymph nodes, areas of skin or other organs, according to the American Cancer Society. Alternative treatments are typically tried before chemotherapy. PD-1, or Programmed Cell Death Protein 1, therapy helps the immune system fight cancer cells. The five-year survival rate for those with a distant spread of melanoma -- with the cancer in the lungs, liver, skin or lymph nodes -- is 35%, based on data collected by the American Cancer Society for people diagnosed between 2014 and 2020. Jones said he underwent two lung surgeries and two lymph node surgeries. The longtime Cowboys owner bought the franchise for $140 million in 1989. The Cowboys were listed as the most valuable franchise in the NFL on Wednesday, topping Sportico's annual rankings with a value of $12.8 billion. Last year, the Cowboys became the first franchise to pass the $10 billion mark.
Yahoo
an hour ago
- Yahoo
Eli Lilly accused of bribing providers to prescribe GLP-1RA drugs
Despite posting record Q2 growth for its blockbuster weight loss and diabetes drug tirzepatide, Eli Lilly is facing legal challenge from a lawsuit filed in Texas that accuses the pharma company of bribing providers to prescribe its drugs. Attorney General for Texas Ken Paxton and Health Choice Alliance claim Eli Lilly 'offered illegal incentives' to medical providers in the southern state so its most profitable drugs, including popular glucagon-like peptide-1 receptor agonist (GLP-1RA) medications tirzepatide, marketed as Mounjaro and Zepbound, would be preferentially prescribed to patients. The lawsuit marks the latest legal assault by the attorney general's office, having previously sued Eli Lilly over an industry conspiracy to increase insulin prices. Health Choice Alliance has also filed previous legal action against Eli Lilly in the past. In the latest filing, Paxton and Health Choice Alliance claim that Eli Lilly's actions cost Texas Medicaid 'millions of dollars'. The claimants argue that prescriptions were covered by the government insurance programme, resulting in claims to Texas Medicaid that were 'tainted by Eli Lilly's illegal marketing and quid pro quo arrangements'. As per the filing, Lilly is alleged to have participated in two schemes to induce and influence providers. In the first, the pharma company, with the help of third parties, apparently provided free nursing services. The second scheme alleges that Lilly continues to offer reimbursement support services to get their drugs prescribed over rivals. An Eli Lilly spokesperson told Pharmaceutical Technology that it intends to 'vigorously defend against these allegations'. The spokesperson added: 'Multiple courts and the federal government have rejected claims by this same corporate relator against Lilly as meritless. In fact, the United States Government determined that 'the relators' allegations lack sufficient factual and legal support' in a prior case, explaining that federal healthcare programs have a strong interest in ensuring that, after a physician has appropriately prescribed a medication, patients have access to basic product support relating to their medication." This referred to similar kickback claims previously made by Health Choice Alliance. Lilly was originally sued by the organisation in 2017, alleged to have participated in a 'multi-tiered kickback scheme' along with other pharma companies, including Bayer. This involved offering free nursing services in exchange for preferential drug prescriptions. The case was dismissed a year later by a judge in Texas. In 2021, a court of appeals upheld the prior decision to scrap the case amid attempts to revive the lawsuit. It is also not the first time the state of Texas has accused Lilly of unlawful activities. In October 2024, the attorney general's office sued several drugmakers and pharmacy benefit managers (PBMs) over insulin product prices. According to a statement at the time, Paxton accused manufacturers of a 'conspiracy' to artificially and willingly raise insulin prices and then pay an undisclosed amount back to PBMs in a quid pro quo arrangement. Lilly had a strong Q2 as it extended its lead over rival Novo Nordisk in the GLP-1RA treatment space. The company reported growth of 172% and 68% for Zepbound and Mounjaro, respectively. The two drugs brought in combined sales of $8.57bn in the quarter. "Eli Lilly accused of bribing providers to prescribe GLP-1RA drugs" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
